Symtuza clinical trials
How each study uses symtuza is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the symtuza studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Symtuza
- 3
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
NEAT ID Foundation (1) · Fundacion SEIMC-GESIDA (1) · East Carolina University (1) · Midland Research Group, Inc. (1) · ADRIANO LAZZARIN, MD (1)
Often tested with
Tested in the same studies.
Bictegravir, emtricitabine, tenofovir alafenamide, drug combination (2) · Dolutegravir (2) · Lamivudine (1)
Studies
Open first, then newest update. How each study uses symtuza is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight GainRecruitingPhase 4East Carolina UniversityNCT05463783Written as SymtuzaHow we know
- The Late Presenter Treatment Optimisation StudyCompletedPhase 3NEAT ID FoundationNCT03696160Written as SymtuzaHow we know
- Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)TerminatedPhase 4Midland Research Group, Inc.NCT04240210Written as SymtuzaHow we know
- A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)CompletedPhase 4Fundacion SEIMC-GESIDANCT03685500Written as Symtuza® (TAF/FTC/DRV/c)How we know
- Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).Status unknownPhase 4ADRIANO LAZZARIN, MDNCT04225325Written as SYMTUZAHow we know